Lisata Therapeutics, based in Basking Ridge, New Jersey, focuses on developing therapies for advanced solid tumors, with its lead candidate LSTA1 enhancing anti-cancer drug penetration in tumors. The company also explores CD34+ cell therapy for various diseases, including critical limb ischemia and diabetic kidney disease.
LSTA has been in the news recently: Kristen Oelschlager, COO of Castle Biosciences, was awarded the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year for her effective leadership. Additionally, MBX Biosciences, Inc. successfully raised about $187.7 million from its IPO on September 16, 2024.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
